RVNC U.S.: Nasdaq

    Revance Therapeutics Inc.

    After Hours
    Last Updated: Sep 9, 2022 7:59 p.m. EDT Delayed quote

    $ 28.00

    -0.47 -1.65%
    After Hours Volume: 169.13K
    Close Chg Chg %
    $28.47 3.17 12.53%
    Advanced Charting
    Volume: 5.25M 65 Day Avg: 923.86K
    568% vs Avg
    25.34 Day Range 29.51
    11.27 52 Week Range 30.00

    Your Watchlists

    Customize MarketWatch

    Have Watchlists? Log in to see them here or sign up to get started.

    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    No Saved Watchlists

    Create a list of the investments you want to track.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    RVNC Overview

    Key Data

    • Open $26.13
    • Day Range 25.34 - 29.51
    • 52 Week Range 11.27 - 30.00
    • Market Cap $1.85B
    • Shares Outstanding 73.11M
    • Public Float 68.14M
    • Beta 1.23
    • Rev. per Employee $200.66K
    • P/E Ratio N/A
    • EPS -$3.84
    • Yield N/A
    • Dividend N/A
    • Ex-Dividend Date N/A
    • Short Interest 8.09M 08/15/22
    • % of Float Shorted 11.88%
    • Average Volume 923.86K


    5 Day
    • 31.02%
    1 Month
    • 26.59%
    3 Month
    • 137.05%
    • 74.45%
    1 Year
    • 4.98%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 10 Full Ratings

    Recent News

    Health Care Up on Rebound in Risk Appetite -- Health Care Roundup

    Read full story

    FDA Approves New Botox Competitor From Revance Therapeutics

    Read full story

    Asana, GameStop, Moderna, Revance, and More Stock Market Movers Thursday

    Revance Therapeutics Shares Rise on FDA Approval of Botox Rival

    Read full story

    Revance Stock Is Plunging. The FDA Won’t Clear a Treatment for Frown Lines.

    Revance Therapeutics plummets after FDA said it can't approve BLA of treatment for frown lines

    Shares of Revance Therapeutics Inc. plummeted 34.7% toward an 18-month low in premarket Monday, which puts them on track for a record one-day selloff, after the company said the the Food and Drug Administration issued a C...

    Revance's stock falls 35% after FDA says it won't approve the company's frown-line injection

    Shares of Revance Therapeutics Inc. tumbled 35.3% in premarket trading on Monday after the company said Friday that the Food and Drug Administration had declined to approve Revance's application for a frown-line treatment...

    Revance CEO Dan Browne steps down due to 'misjudgment in handling employee matter'

    Biotech Revance Therapeutics Inc. said Monday it has named Mark J. Foley as chief executive, replacing Dan Browne who has stepped down due to a misjudgment in handling an employee matter. Browne has also resigned from the...

    Revance Therapeutics started at buy with $50 stock price target at Stifel Nicolaus

    Revance Therapeutics reaches licensing agreement with Fosun Pharmaceutical over botox formulation RT002

    Shares of Revance Therapeutics Inc. were up 1.9% in premarket trade Tuesday after the company announced it had entered an agreement with Shanghai Fosun Pharmaceutical Industrial Development Co. to give Fosun exclusive rig...

    Revance's stock halted for news until 8:35 a.m. Eastern

    Revance to receive $30 mln upfront, potential milestone payments of up to $230.5 mln as part of license deal

    Revance Therapeutics enters China license agreement with Shanghai Fosun Pharmaceutical

    Read full story

    Allergan’s Stock Is Headed for a Face-Lift

    Read full story

    Mylan shares bounce on plans for Botox copycat, 2018 drug launches

    Read full story

    Charting the Market

    UPDATE: Revance stock surges and Allergan drops on positive results for wrinkle injection

    Revance Therapeutics Inc. shares surged nearly 38% in extremely heavy morning trade Tuesday after the company reported positive results for its wrinkle-relaxing injection in two late-stage clinical trials. If approved, th...

    Allergan stock drops 3% after rival product's positive trial results

    Revance stock surges 32% on positive results for wrinkle injection in late-stage trial

    Revance Therapeutics stock price target raised to $32 vs. $22 at SunTrust Robinson

    With New Growth Avenues, Analysts Boost Price Targets For This Botox Competitor

    on Benzinga.com

    Revance (RVNC) Gets FDA Nod for Anti-Wrinkle Product, Stock Up

    FDA approves Revance Therapeutics' (RVNC) Daxxify as a long-acting neuromodulator with a strong label that includes 36-week efficacy data from the SAKURA clinical program.

    on Zacks.com

    Analyst Ratings for Revance Therapeutics

    on Benzinga.com

    Needham Maintains Buy Rating for Revance Therapeutics: Here's What You Need To Know

    on Benzinga.com

    What 5 Analyst Ratings Have To Say About Revance Therapeutics

    on Benzinga.com

    5 Analysts Have This to Say About Revance Therapeutics

    on Benzinga.com

    Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday

    on Benzinga.com

    Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary

    on Benzinga.com

    Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session

    on Benzinga.com

    Needham Reaffirms Their Buy Rating on Revance Therapeutics (RVNC)

    Needham analyst Serge Belanger maintained a Buy rating on Revance Therapeutics (RVNC - Research Report) today and set a price target of $35.00. The company's shares opened today at $24.72.Belanger covers the Healthcare sec...

    on TipRanks.com

    Revance (NASDAQ:RVNC) Bounces on DAXXIFY FDA Approval

    Shares of neuromodulators developer Revance Therapeutics  (NASDAQ:RVNC) continue to fly higher today after the biotechnology company’s peptide-formulated neuromodulator – DAXXIFY won approval from the U.S. Food and Drug Ad...

    on TipRanks.com

    AAPL Stock Alert: 13 Takeaways From the Latest Apple Event 2022

    on InvestorPlace.com

    Why Is Revance Therapeutics (RVNC) Stock Soaring Today?

    on InvestorPlace.com

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    on Benzinga.com

    Revance Shares Shoot Higher As FDA Cleared DAXXIFY Injection For Frown Lines

    on Benzinga.com

    Why Asana Is Trading Higher By 24%; Here Are 24 Stocks Moving Premarket

    on Benzinga.com

    Revance Therapeutics (RVNC) Gets a Buy from Mizuho Securities

    In a report released today, Uy Ear from Mizuho Securities maintained a Buy rating on Revance Therapeutics (RVNC - Research Report), with a price target of $26.00. The company's shares opened today at $20.06.Ear covers the ...

    on TipRanks.com

    10 Health Care Stocks With Whale Alerts In Today's Session

    on Benzinga.com

    Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know

    on Benzinga.com

    10 Health Care Stocks With Whale Alerts In Today's Session

    on Benzinga.com

    Revance Therapeutics Inc.

    Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.


    Name Chg % Market Cap
    Ionis Pharmaceuticals Inc. 7.39% $6.28B
    Biogen Inc. 2.16% $30.18B
    Johnson & Johnson 0.05% $434.84B
    MediciNova Inc. 2.76% $106.43M